Caveolin-1 plays a crucial role in atherosclerosis, which is mainly attributed to its effects on low-density-lipoprotein (LDL) transcytosis. However, caveolin-1 has also been implicated in the regulation of inflammation. We investigated the effects of caveolin-1 deficiency in atherosclerosis with its accompanying changes in plaque-and lymphoid-related immunology and inflammation. Cav1 ؊/؊ Apoe ؊/؊ bone marrow was associated with an anti-inflammatory T-cell profile. Our study reveals that nonhematopoietic caveolin-1 determines plaque size, whereas hematopoietic caveolin-1 regulates lymphoid immune-modulation. However, both are required for phenotypic modulation of plaques.-Engel,
Caveolae are 50-to 100-nm cell surface plasma membrane invaginations that are present in the majority of terminally differentiated cell types and are putatively involved in many cellular processes, including cholesterol homeostasis and transport, endocytosis, transcytosis, and signal transduction (1, 2) . Caveolae are present in many cell types, such as endothelial cells (ECs), smooth muscle cells (SMCs), adipocytes, fibroblasts, and macrophages (M⌽s). Studies using modulation of caveolin-1, the most important coat protein of caveolae, have elucidated many of its cellular functions (3, 4) .
In ECs, caveolin-1 mediates transcytosis of LDL (5), supports CD36-mediated transcytosis (6) , and negatively regulates endothelial nitric oxide synthase (eNOS) activity (7, 8) . While it regulates the formation, storage and mobilization of lipid stores in adipocytes (9) , caveolin-1 impairs SMC migration by inhibiting signaling via the mitogen-activated protein kinase (MAPK) pathway (10) .
Interestingly, in immune cells, caveolae appear present only in cells of the myeloid lineage but not in cells of the lymphoid lineage, with the exception of particular T cell leukemia cell lines and bovine lymphocytes (11, 12) . In M⌽s, caveolin-1 was reported to exert anti-inflammatory effects on inflammatory stimuli with strong reductions in tumor necrosis factor ␣ (TNF-␣), interleukin 6 (IL-6), and increased production of IL-10 (13). Caveolin-1 also appears to be an early marker of macrophage apoptosis (14) . In neutrophils, deficiency of caveolin-1 decreases their oxidant production, their adhesion and transendothelial migration (15) .
In recent years, caveolin-1 has been ascribed a caus-ative role in several diseases, such as cancer (16) , type 2 diabetes (17) , obesity (9) , hypertrophic cardiomyopathy (18) , pulmonary hypertension and fibrosis (19, 20) , hypercalciuria, urolithiasis, retinal degenerative diseases, and rheumatoid arthritis (2, 4) , but also in vascular pathologies, such as neointima formation and atherosclerosis (21) (22) (23) (24) (25) .
The role of caveolin-1 in atherosclerosis is paradoxical. Although caveolin-1 is expressed in the majority of vascular related cell types [vascular smooth muscle cells (VSMCs), ECs, M⌽s], its expression in human and rabbit atherosclerotic plaques decreases with disease severity (22, 26 -28) . Moreover, loss of caveolin-1 in human plaques correlates with plaque vulnerability and provides a prognostic value for cardiovascular events (22) . A similar phenotype was observed in models of neointima formation, in which loss of caveolin-1 accelerated lesion formation (21) . However, in atherosclerotic mouse models, deficiency of caveolin-1 appeared atheroprotective, as Cav1 Ϫ/Ϫ Apoe Ϫ/Ϫ mice exhibited a 70% decrease in plaque area, despite the presence of hypercholesterolemia (23) (24) (25) . This phenotype was attributed mainly to defective transendothelial migration of LDL, which was confirmed in atherosclerotic mouse models with EC-specific overexpression of caveolin-1 (23) (24) (25) .
Since caveolin-1 also plays a crucial role in the internalization of receptors important in inflammation, and thus, in their signal transduction (29), we investigated whether the immune system itself is affected by caveolin-1 deficiency and therefore affects atherosclerosis. Moreover, we aimed to investigate how plaque phenotype, inflammatory status, and leukocyte adhesion are changed during early and late stages of the disease and how cell type-specific loss of caveolin-1 affects atherosclerosis. We show that total caveolin-1 deficiency decreases atherosclerosis and plaque inflammation. This is mediated by a reduced influx of leukocytes, and a systemic anti-inflammatory T-lymphocyte profile. In addition, we show that especially the nonhematopoietic caveolin-1-expressing cells (ECs, VSMCs) determine plaque size, while hematopoietic caveolin-1-expressing cells mediate changes of the systemic and plaque-restricted immunological profile.
MATERIALS AND METHODS

Animals
All animal procedures were approved by the animal experimental committee of University Maastricht and performed in accordance with the institutional guidelines. To generate Cav1 ϩ/ϩ Apoe Ϫ/Ϫ and Cav1 Ϫ/Ϫ Apoe Ϫ/Ϫ mice, Cav1 Ϫ/Ϫ mice (C57Bl6 background; provided by R.V.S.) were backcrossed 7 generations to Apoe Ϫ/Ϫ mice (C57Bl6 background; Charles River, L'Arbresle, France). All mice were fed a standard fat diet (cat. V1535; ssniff Spezialdiäten GmbH, Soest, Germany), had ad libitum access to food and water, and were housed under a 12-h light-dark cycle. At the age of 17 or 26 wk, male and female mice were sacrificed (nϭ15 for each genotype and time point) by an overdose of pentobarbital.
Blood was subsequently obtained from the right ventricle, and plasma was used for cholesterol measurements and lipoprotein profiles. Thereafter, the arterial tree was perfused through the left ventricle with 10 ml phosphate buffered saline (PBS, containing 0.1 mg/ml sodium nitroprusside) to achieve vessel relaxation and 10 ml 1% paraformaldehyde (PFA) for tissue fixation. The aortic arch and its main branch points (brachiocephalic trunk, left common carotid artery, and left subclavian artery) were taken out and fixed overnight in a 1% PFA solution. Two additional groups of mice (male nϭ6; female nϭ5-6) were sacrificed for flow cytometric analysis of blood, spleen, and lymph nodes (pool of mesenteric, salivary, and axial lymph nodes) at the age of 17 wk. Mice were kept on the same protocol as mentioned above.
Histology and morphometry of atherosclerotic plaques
The aortic arch was embedded longitudinally in paraffin and cut into 40 consecutive 4-m sections (nϭ15 for each phenotype and time point). Twenty slides that best represented the 3-dimensional structure of the arch were chosen for the additional immunohistochemical analysis. Four sections of the aortic arch (20 m apart) were stained with hematoxylin and eosin (HE), and the atherosclerotic lesions were classified as initial or advanced according to the Virmani classification (30) . This procedure enabled us to calculate the individual plaque area per type (initial or advanced). Furthermore, we quantified the number of cells per lesion and the number of plaques per arch, by calculating the mean plaque number of the 4 HE-stained sections, which can lead to a plaque number per arch Ͻ 1. For each plaque, area and lipid core content was determined using a microscope coupled to a computerized morphometry system (Qwin 3.5; Leica, Wetzlar, Germany). Morphometric parameters were determined as described previously (31) .
Immunohistochemistry
Immunohistochemistry was performed on paraffin sections of the aortic arch (nϭ15 for each phenotype and time point): ␣ smooth muscle actin monoclonal antibody (1:500 dilution; Dako, Glostrup, Denmark) as a marker for SMCs; CD3 polyclonal antibody (1:200 dilution; Dako) to detect T lymphocytes; CD45 polyclonal antibody (1:5000 dilution; BD Bioscience, Bedford, MA, USA) to detect total leukocytes; Ly6G monoclonal antibody (1:200 dilution; BD Bioscience) to detect Ly6G positive neutrophils; Mac3 monoclonal antibody (1:30 dilution; BD Bioscience) to detect macrophages; Foxp3 monoclonal antibody (1:50 dilution, Ebioscience, San Diego, CA, USA) to detect regulatory T cells; Perl's iron staining (1:1 solution of 2 g potassium hexacyanoferrate dissolved in 100 ml distilled water and 54 ml 37% concentrated hydrochloric acid in 1000 ml distilled water) to detect bleeding; anti-von Willebrand factor (1:500 dilution; Dako) to detect disrupted endothelium, and, finally, caspase-3 polyclonal antibody (1:20 dilution; Cell Signaling, Danvers, MA, USA) to detect apoptotic cells. To determine the relative amount of T cells, leukocytes, macrophages, and regulatory T cells, the number of positive cells per lesion was divided by the total number of cells per lesion, as determined by number of nuclei per lesion. The number of Ly6G ϩ neutrophils was expressed as positive cells per square millimeter of plaque. The staining for SMCs and collagen was evaluated quantitatively with Qwin 3.5. Anti-caveolin-1 polyclonal antibody (1: 800 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was used to localize caveolin-1 in the plaque and to prove the complete absence of caveolin-1 in Cav1positive (staining visible) and negative (no staining at all) cases. The VCAM-1 staining was performed on frozen sections from mouse aortic roots, using a rat-anti-mouse monoclonal antibody (1:200 dilution; BD Bioscience).
Bone marrow transplantation (BMT)
Female Cav1 ϩ/ϩ Apoe Ϫ/Ϫ and Cav1 Ϫ/Ϫ Apoe Ϫ/Ϫ deficient mice (8 -9 wk old) were transferred to filter-top cages and administered water containing antibiotics (polymyxine B sulfate, 60,000 U/L, and neomycin, 100 mg/L) 1 wk before BMT. At 1 d prior to BMT, the mice were lethally irradiated (10 Gy, 0.5 Gy/min; Philips MU15F/225 kV; Philips, Hamburg, Germany). The next day, the irradiated mice were intravenously injected with 10 7 bone marrow cells of male Cav1
and Cav1 Ϫ/Ϫ Apoe Ϫ/Ϫ mice, respectively, generating 4 different groups (nϭ5-8/group). Mice were maintained on the antibiotic water treatment for an additional 4 wk to restore bone marrow function. Following this recovery time, the mice were administered a Western-type diet (0.21% cholesterol, cat. 4621.06; Hope Farms, Woerden, The Netherlands). After 10 wk of Western-type diet, the mice were sacrificed, and aortic arches were processed and analyzed as described above. In addition, blood, spleen, and lymph nodes were taken for flow cytometric analysis.
Flow cytometry and blood count
Blood, spleen, and lymph nodes were collected, processed, and stained with fluorescent antibodies against CD3, CD4, CD8, CD25, Foxp3, B220, CD11b, Ly6C, and Ly6G (all eBiosciences, San Diego, CA, USA), and analyzed as described previously (ref; 32; nϭ5-8/group). Briefly, spleen and lymph nodes were homogenized, filtered through a 70-m mesh, and subjected to red blood cell lysis. All cells were stained in FACS buffer (1ϫ PBS, 0.5% BSA, and 0.01% NaN3). Staining for blood count analyses was conducted using antibodies to CD45, CD115, Gr1, CD19, and CD3 (all eBiosciences) in HBSS with 0.3 mM EDTA and 0.1% BSA. Blood was subjected to red blood cell lysis. Cell counts were estimated utilizing CountBright absolute counting beads (Invitrogen, Carlsbad, USA). All flow cytometry analysis was performed on a BD Canto II (BD Bioscience).
Cholesterol measurement and lipoprotein profiles
Plasma cholesterol levels were measured using a colorimetric assay (CHOD-PAP 11491458216; Roche, Mannheim, Germany; nϭ15 for each genotype and time point). Lipoprotein profiles were determined on pooled plasma samples using an Akta Basic chromatography system with a Superose 6PC 3.2/30 column (Amersham Biosciences, Roosendaal, The Netherlands). Blood samples of mice were collected, and the plasma of 3 mice (20 l each) with the same genotype was pooled. Samples were loaded onto the column. The plasma was passed over the columns at a flow rate of 0.5 ml/min, and 36 fractions were collected.
Quantitative polymerase chain reaction (qPCR)
RNA was isolated from aortic arches by homogenizing the tissue in trizol, followed by a purification step (nucleo spin RNAII; Marcherey & Nagel, Düren, Germany) and quantified using a Nanodrop 1000 (Thermo Fisher Scientific, Wilmington, DE, USA; nϭ7/genotype). Total RNA (0.2 g) was reverse transcribed to generate cDNA employing the SuperScript VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Real-time PCR employing Express SYBR GreenER qPCR SuperMix (Invitrogen) and primers as indicated in Table 1 was carried out on an ABI 7900 HT Fast RT-PCR system (Applied Biosystems, Foster City, CA, USA). The reactions were performed in duplicate, utilizing cDNA corresponding to 5 ng RNA. Cycling conditions were as follows: 95°C for 20s followed by 40 cycles of 95°C for 5s and 60°C for 20 s. Specificity was confirmed by appearance of a single peak in a final dissociation step (60 -95°C, 2% ramp rate). Data were analyzed on the basis of the relative expression method with the formula 2 Ϫ⌬⌬CT , where ⌬⌬C T ϭ ⌬C T (sample) Ϫ ⌬C T (calibrator ϭ average C T values of all samples), and ⌬C T is the C T of the housekeeping gene [glyceraldehyde-3-phosphate dehydrogenase (GAPDH)] subtracted from the C T of the target gene.
Enzyme-linked immunosorbent assay (ELISA)
CCL-2 levels in sera were analyzed by using a commercial ELISA (R&D Systems, Minneapolis, MN, USA) according to the protocol provided by the manufacturer.
Intravital microscopy
Intravital microscopy of the left carotid artery was performed as described previously (33, 34) . Leukocyte adhesion was visualized by i.v. injection of rhodamine 6G. For luminal detection of chemokines presented on the endothelium, 50 l of Protein G Fluoresbrite YG Microspheres (Polysciences Inc., Warrington, PA, USA) were coupled to 50 g of poly- 
clonal antibodies to CCL2 (nϭ6 mice/genotype for leukocyte adhesion and nϭ7 mice/genotype for anti-CCL-2 directed beat adhesion). Beads and antibodies were incubated for 30 min at room temperature, washed twice, and subsequently injected i.v. after exposure of the external carotid. Antibody/ bead complexes were allowed to circulate for 15 min, and immobilized complexes were detected by intravital microscopy using an Olympus BX51 microscope (Olympus, Hamburg, Germany) equipped with a Hamamatsu 9100 -02 EMCCD camera (Hamamatsu Photonics, Hamamatsu City, Japan) and a ϫ10 saline-immersion objective. For image acquisition and analysis, Olympus cell r software was used.
Statistical analysis
All data are expressed as means Ϯ se. 
RESULTS
Caveolin-1 expression in atherosclerosis
Caveolin-1 was expressed in all stages of murine atherosclerosis, ranging from intimal xanthomas to fibrous cap atheromata. Interestingly, as reported for human plaques, the expression of caveolin-1 decreased with lesion progression, suggesting that loss of caveolin-1 indicates plaque progression (Fig. 1A, B) . Most of the caveolin-1 protein was present in ECs, but also in SMCs and M⌽s.
Caveolin-1 deficiency increases lipid levels but dramatically decelerates plaque progression
Plasma cholesterol levels were substantially increased in the Cav1
Apoe Ϫ/Ϫ mice after 17 and 26 wk of a normal chow diet, corroborating previous studies ( Fig.  1C; refs. 23, 24 ). Gel-filtration chromatography revealed that cholesterol content was especially increased in the very-low-density lipoprotein-(VLDL) and LDLsized fractions. These findings are remarkable, as it has been reported that Cav-1 Ϫ/Ϫ mice display an impaired VLDL production (35) . Nevertheless, a disturbed degradation of the VLDL particles might cause the elevated VLDL levels. The involvement of caveolin-1 in insulin signaling could be part of the mechanism behind this phenomenon. No changes were observed in the highdensity lipoprotein (HDL) fraction (Fig. 1D) . To analyze the effect of caveolin-1 deficiency on atherosclerotic plaque initiation and progression, we examined 2 experimental groups sacrificed after 17 and 26 wk of normal chow diet. At 17 wk of age, aortic arches of the mice exhibited early signs of atherosclerosis, with plaques predominantly composed of M⌽ foam cells ( Fig. 2A, B) . At 26 wk of age, atherosclerosis had progressed toward an advanced stage, with the majority of plaques containing a lipid core and/or a fibrous cap (Fig. 2C, D) . The lower abundance of initial plaques in the aortic arch of 26-wk-old mice can be explained by the observed atherosclerosis progression and the fact that different initial plaques can fuse over time. Despite the dramatic increase in plasma cholesterol in the VLDL and LDL fraction (Fig. 1C, D) , lack of caveolin-1 reduced total plaque area in the aortic arch 6.9-to 15-fold (Fig. 2E ). This was paralleled by a (Fig. 2F) and by a dramatic decrease in plaque area of individual advanced plaques (Fig. 2G) , indicating that not only plaque initiation, but also progression, is inhibited in the absence of caveolin-1. Similar results were obtained using female mice, and no differences compared to male mice with respect to the above mentioned parameters were observed (Supplemental Table S1A ).
Caveolin-1 deficiency impairs leukocyte adherence to the endothelium and abolishes plaque inflammation
An initial step in atherosclerosis development is the adhesion and extravasation of leukocytes through the EC layer. To investigate whether leukocyte adhesion to the endothelium differs in Cav1 ϩ/ϩ Apoe Ϫ/Ϫ and Cav1 Ϫ/Ϫ Apoe Ϫ/Ϫ mice, we performed intravital microscopy of the carotid artery bifurcation in rhodamine 6G-injected mice. Although there was no effect on leukocyte rolling (Cav1 ϩ/ϩ Apoe Ϫ/Ϫ 29.8Ϯ9.0 vs. Cav1
33.0Ϯ14.8 cells/field), significantly fewer leukocytes adhered to the endothelium of Cav1 Ϫ/Ϫ Apoe Ϫ/Ϫ mice compared to their wild-type controls (Fig. 3A and Supplemental Videos S1, S2). Injection of antibodycoated beads directed against CCL-2 demonstrated that Cav1
Apoe Ϫ/Ϫ mice had a decreased presentation of CCL-2 at the endothelial-monocyte interface (Fig. 3B) . Interestingly, CCL-2 mRNA levels within the plaque (Cav1 ϩ/ϩ Apoe Ϫ/Ϫ 1.4Ϯ0.3 vs. Cav1 Table S1B ). In addition, VCAM-1 was almost absent on the endothelium of Cav1 (Fig. 3C) , whereas intercellular adhesion molecule-1 (ICAM-1) expression was not different (Table 2) . Our results clearly show that caveolin-1 plays a crucial role in leukocyte adhesion and extravasation into the arterial wall, particularly by affecting endothelial VCAM-1 expression and CCL-2 presentation at the leukocyte-endothelial interface. The decreased plaque progression was accompanied by changes in plaque composition. In advanced plaques of 26-wk-old Cav1 (Fig. 3E) . In addition, plaque infiltration by neutrophils was impaired in young and old Cav1 
Apoe
Ϫ/Ϫ 1.2Ϯ0.3, P Ͻ 0.05) with far less neutrophil abundance in plaques of old mice (Fig. 3F) collagen (Sirius red), ␣ smooth muscle actin, regulatory T cells, disrupted epithelium (von Willebrand factor) and iron deposition (Perl's iron) revealed no differences between groups (Supplemental Table S2 ). These data show that caveolin-1 deficiency prevents plaque inflammation and apoptosis.
Caveolin-1 deficiency increases the regulatory T-cell population
To assess the mechanism by which caveolin-1 affects immune cell numbers or subset distribution, we analyzed blood, spleen, and lymph nodes of Cav1 ϩ/ϩ Apoe Ϫ/Ϫ and Cav1 Ϫ/Ϫ Apoe Ϫ/Ϫ mice using flow cytometry. Blood counts for T cells, B cells, neutrophils, and monocytes revealed no differences between the genotypes (Fig. 4) .05; Fig. 5 ), indicating that caveolin-1 deficiency changes T-cell homeostasis toward an anti-inflammatory, regulatory T-cell profile. Analysis of blood and spleen samples revealed similar results. No differences could be found in blood, spleen, and lymph node samples concerning B cells, monocyte subsets (Ly6Chigh/low), and granulocytes. These data show that, as no regulatory T cells could be detected in the atherosclerotic plaques, caveolin-1 deficiency induces a regulatory T-cell profile, which, probably together with regulatory T cells in the adventitia, contributes to the observed anti-inflammatory plaque phenotype of Cav1
Intricate interplay of hematopoietic and nonhematopoietic caveolin-1 in atherosclerosis
As our results showed that total loss of caveolin-1 leads to atheroprotection and changes in immune cell subsets, we aimed to investigate whether loss of caveolin-1 (Fig. 6A) 
Apoe Ϫ/Ϫ reconstituted 61.0Ϯ0.63) and slightly decreased the number of regulatory T cells (Fig. 7) . These data suggest that the nonhematopoietic caveolin-1 compartment is responsible for plaque growth and transendothelial migration of macrophages, while the combination of nonhematopoietic and hematopoietic caveolin-1 appears to be required for immune modulation in lymphoid organs and in atherosclerotic plaques.
DISCUSSION
In recent years, caveolae have been subject to intensive research in cardiovascular science, and the analysis of caveolin-1 deficient mice has revealed many of its functions. Besides mediating vascular homeostasis (e.g., inhibition of eNOS, ref. The groups of Lisanti (23) and Sessa (24, 25) were the first to show that deficiency of caveolin-1 decreased atherosclerosis, despite elevating plasma lipid levels. Recent studies especially stressed the importance of endothelialderived caveolin-1 in the pathogenesis of atherosclerosis. Cav1
Apoe
Ϫ/Ϫ mice that were reconstituted with a transgene containing canine caveolin-1 under a preproendothelin-1 promotor have similar atherosclerosis levels and plaque features compared to control Apoe Ϫ/Ϫ mice (24) . Furthermore, Apoe Ϫ/Ϫ mice containing the respective transgene exhibit features of accelerated atherosclerosis compared to control Apoe Ϫ/Ϫ mice (25) . Mechanistically, loss of endothelial cell caveolin-1 resulted in impaired transendothelial LDL transport (5, 24, 25) , promoted NO production (7, 39, 40) , and reduced the expression of adhesion molecules (41) (42) (43) .
However, the effect of caveolin-1 on immune cells in atherosclerosis has not been addressed before. In the present paper, we show for the first time that caveolin-1 has two divergent functions in modulating atherosclerosis. The first function is clearly dependent on endothelialcell caveolin-1, where caveolin-1 mediates the expression of VCAM, and affects deposition of CCL-2 at the endothelial cell/monocyte interface. This results in decreased leukocyte adhesion to the arterial wall in Cav1
mice, and consequently, in smaller atherosclerotic plaques.
The second function of caveolin-1 in atherosclerosis is related to the hematopoietic compartment. Plaques of Cav1 Ϫ/Ϫ Apoe Ϫ/Ϫ mice contain fewer macrophages, neutrophils, and T cells. This can be caused by the reduced expression of CCL-3, CCL-4 and CCR-5 on immune cells, which will consequently impair their chemotactic capacity and immune reactivity. Surprisingly, CCL-2 mRNA levels were not affected, whereas the deposition of CCL-2 on endothelial cells was decreased in Cav1
Ϫ/Ϫ mice. This can be explained by the dependency of leukocyte adhesion molecule expression on caveolae and the association of caveolin-1 with CCL-2 presentation and distribution (42) . Our results are in line with these findings and underscore the CCL-2/CCR-5-dependent contributions to neutrophil infiltration into early atherosclerotic plaques reported by Drechsler et al. (34) .
Interestingly, Cav1
Ϫ/Ϫ Apoe Ϫ/Ϫ mice exhibit enhanced numbers of regulatory T cells in blood, spleen, and lymph nodes, as well as reduced numbers of CD4 ϩ effector T cells, an immunological phenotype associated with protection against atherosclerosis (41) . In human plaques, however, loss of caveolin-1 expression is associated with atherosclerotic plaque vulnerability, with plaques contain- ing elevated levels of inflammatory cells, IL-6, IL-8, and matrix metalloproteinase-9 (22) . This discrepancy might be explained by the fact that the cellular composition of plaques changes during plaque progression, that certain cell-types have different numbers of caveolae, and that caveolin-1 exerts divergent actions in different cell types.
Our reciprocal BMTs show that both endothelial and hematopoietic caveolin-1 are important in the pathogenesis of atherosclerosis. Nonhematopoietic caveolin-1 critically determines plaque mass, whereas hematopoietic caveolin-1 especially mediates plaque phenotype and affects the systemic immune system.
Until now, only scattered and paradoxical information has existed on the function of caveolin-1 in inflammation and in the immune system. Caveolin-1 is involved in sequestering P42/44 MAPK members, signaling proteins involved in cytokine production, thereby preventing inflammation (44) . Likewise, caveolin-1 can bind toll-like receptor 4 and prevent the release of TNF-␣ and IL-6 (45). Furthermore, cyclooxygenase-2 binds to caveolin-1 at the endoplasmic reticulum, leading to its rapid degradation (46) . In M⌽s, caveolin-1 acts as an immune modulator on stimulation with lipopolysaccharide, thereby suppressing the release of TNF-␣ and IL-6, and inducing the anti-inflammatory cytokine IL-10 (13, 47). However, caveolin-1 is also involved in proinflammatory actions. Caveolin-1 is reported to enhance the oxidant production, adhesion capacities, and transendothelial migration of neutrophils (15) , to increase apoptosis in M⌽ (14) , and to induce antigen-specific T cell proliferation and activation via interaction with the costimulatory molecules CD26 (48) . Caveolin-1 plays an important role during bacterial infections in which it promotes the entrance of bacteria into host cells causing alterations in innate immunity and activating inflammatory responses (49) .
In our study, we could elucidate the function of hematopoietic caveolin-1 and showed that in atherosclerosis caveolin-1 deficiency leads to an anti-inflammatory state. Our results highlight the important role for caveolae in atherosclerosis. Although the major role for caveolin-1 in atherosclerosis was heretofore considered to be the transporting of LDL into the vascular wall, our study reveals a clear function of caveolin-1 in mediating inflammatory and immunological actions in vascular disease. These findings may allow for the development and investigation of new drugs that target caveolin-1. Nonetheless, the precise actions of caveolin-1 in immune cells have been unknown to date and should still be subject to further investigation.
